Journal
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
Volume 51, Issue 3, Pages 258-266Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/FJC.0b013e3181624b22
Keywords
fibrates; PPAR; LXR; ABCA1; HDL; hepatocytes; cholesterol
Ask authors/readers for more resources
Fibric acid-shaped drugs raise high-density lipoprotein (HDL) cholesterol by upregulating the HDL-related genes through activating peroxisome proliferater activated receptor (PPAR)-alpha. We investigated the effects of fibrates to induce expression of adenosine triphosphate-binding cassette transporter A1 (ABCA1) and increase HDL biogenesis in hepatocytes. Fenofibrate, bezafibrate, gemfibrozil, and LY518674 were tested for HepG2 cells and primary-cultured mouse hepatocytes. All the compounds examined increased ABCA1 expression and HDL biogenesis dependent on PPAR alpha in association with the liver X receptor alpha upregulation. While fenofibrate and LY518674 showed exclusive dependency on PPARa for these activities, bezafibrate and gemfibrozil exhibited dependency on PPAR beta/delta and PPAR gamma as well. On the other hand, cholesterol-enrichment of HDL may involve PPAR gamma for fenofibrate and bezafibrate, and PPAR beta/delta for the fibrates examined except for bezafibrate. We concluded that fibrates enhance expression of ABCA1 in hepatocytes to contribute to increase of the HDL biogenesis in a PPAR-dependent manner, whether exclusively or nonexclusively on PPAR alpha.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available